High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Nov 27

PMID 34829307

Citations 25

Authors

Barbara Ruaro

Elisa Baratella

Paola Confalonieri

Barbara Wade

Cristina Marrocchio

Pietro Geri

Annalisa Busca

Riccardo Pozzan

Alessia Giovanna Andrisano

Maria Assunta Cova

Marco Confalonieri

Francesco Salton

Affiliations

Soon will be listed here.

Abstract

The diagnosis and classification of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is essential to improve the prognosis of systemic sclerosis (SSc) patients. The risk-stratification of disease severity and follow-up requires a multidisciplinary approach, integrating high-resolution computed tomography (HRTC) of the lung, pulmonary function tests (PFT), along with clinical and symptomatic evaluations. The use of HRCT in detecting SSc-ILD is not so much based on a definitive validation, but rather reflects the widespread clinician recognition of dissatisfaction with other modalities. However, due to the heterogeneity of SSc-ILD and the potential absence of symptoms in early or mild disease, it is prudent to consider as many parameters as possible in the assessment and monitoring of newly diagnosed patients. An early diagnosis meets the primary goal, i.e., the prevention of disease progression. The current first line treatment regimens are mainly centered on immunosuppressive therapy. This review assesses the role HRCT plays in optimizing care and improving clinical outcomes in SSc-ILD patients.

Citing Articles

Lung Ultrasound for Assessment of Interstitial Lung Disease in Systemic Sclerosis: Relationship With High-Resolution Computed Tomography and Nailfold Capillaroscopy.

Elziaty R, Aboelyazeed A, Hegazy S, Khalifa A, Khalil S Clin Med Insights Arthritis Musculoskelet Disord. 2025; 18:11795441251318050.

PMID: 40008078 PMC: 11848898. DOI: 10.1177/11795441251318050.

Transthoracic Lung Ultrasound in Systemic Sclerosis-Associated Interstitial Lung Disease: Capacity to Differentiate Chest Computed-Tomographic Characteristic Patterns.

Rotondo C, Busto G, Rella V, Barile R, Cacciapaglia F, Fornaro M Diagnostics (Basel). 2025; 15(4).

PMID: 40002639 PMC: 11854868. DOI: 10.3390/diagnostics15040488.

Predictive Value of Flow Cytometry Quantification of BAL Lymphocytes and Neutrophils in ILD.

Novoa-Bolivar E, Ros J, Perez-Fernandez S, Campillo J, Lopez-Hernandez R, Gonzalez-Lopez R Cells. 2025; 13(24.

PMID: 39768157 PMC: 11674578. DOI: 10.3390/cells13242066.

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.

Lawrence A, Myall K, Mukherjee B, Marino P Life (Basel). 2024; 14(9).

PMID: 39337985 PMC: 11433497. DOI: 10.3390/life14091203.

Lung Involvement in Pulmonary Vasculitis: A Radiological Review.

Gozzi L, Cozzi D, Zantonelli G, Giannessi C, Giovannelli S, Smorchkova O Diagnostics (Basel). 2024; 14(13).

PMID: 39001306 PMC: 11240918. DOI: 10.3390/diagnostics14131416.

References

Ruaro B, Confalonieri M, Salton F, Wade B, Baratella E, Geri P . The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients. Pharmaceuticals (Basel). 2021; 14(5). PMC: 8145021. DOI: 10.3390/ph14050403. View

Ho K, Reveille J . The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003; 5(2):80-93. PMC: 165038. DOI: 10.1186/ar628. View

Barskova T, Gargani L, Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G . Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Ann Rheum Dis. 2012; 72(3):390-5. DOI: 10.1136/annrheumdis-2011-201072. View

Khanna D, Clements P, Furst D, Chon Y, Elashoff R, Roth M . Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005; 52(2):592-600. DOI: 10.1002/art.20787. View

Khanna D, Tseng C, Farmani N, Steen V, Furst D, Clements P . Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011; 63(10):3078-85. PMC: 3183128. DOI: 10.1002/art.30467. View

Gargani L, Doveri M, dErrico L, Frassi F, Bazzichi M, Delle Sedie A . Ultrasound lung comets in systemic sclerosis: a chest sonography hallmark of pulmonary interstitial fibrosis. Rheumatology (Oxford). 2009; 48(11):1382-7. DOI: 10.1093/rheumatology/kep263. View

Wells A, Hansell D, Corrin B, Harrison N, Goldstraw P, Black C . High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992; 47(9):738-42. PMC: 474812. DOI: 10.1136/thx.47.9.738. View

Lamers R, Kemerink G, Drent M, van Engelshoven J . Reproducibility of spirometrically controlled CT lung densitometry in a clinical setting. Eur Respir J. 1998; 11(4):942-5. DOI: 10.1183/09031936.98.11040942. View

Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M . Interstitial lung disease in systemic sclerosis: where do we stand?. Eur Respir Rev. 2015; 24(137):411-9. PMC: 9487695. DOI: 10.1183/16000617.00002915. View

10.

Faletra F, DAngeli I, Klersy C, Averaimo M, Klimusina J, Pasotti E . Estimates of lifetime attributable risk of cancer after a single radiation exposure from 64-slice computed tomographic coronary angiography. Heart. 2010; 96(12):927-32. DOI: 10.1136/hrt.2009.186973. View

11.

Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M . High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006; 33(9):1789-801. View

12.

Bach P, Mirkin J, Oliver T, Azzoli C, Berry D, Brawley O . Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307(22):2418-29. PMC: 3709596. DOI: 10.1001/jama.2012.5521. View

13.

Ruaro B, Bruni C, Wade B, Baratella E, Confalonieri P, Antonaglia C . Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations With Organ Involvement, Such as Pulmonary Damage?. Front Physiol. 2021; 12:710298. PMC: 8542764. DOI: 10.3389/fphys.2021.710298. View

14.

Sulli A, Ruaro B, Smith V, Pizzorni C, Zampogna G, Gallo M . Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis. J Rheumatol. 2013; 40(5):634-9. DOI: 10.3899/jrheum.121089. View

15.

Pinal-Fernandez I, Pineda-Sanchez V, Pallisa-Nunez E, Simeon-Aznar C, Selva-OCallaghan A, Fonollosa-Pla V . Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis. Clin Rheumatol. 2016; 35(9):2339-45. PMC: 11669075. DOI: 10.1007/s10067-016-3267-0. View

16.

Wells A . Pulmonary function tests in connective tissue disease. Semin Respir Crit Care Med. 2007; 28(4):379-88. DOI: 10.1055/s-2007-985610. View

17.

Kim H, Brown M, Elashoff R, Li G, Gjertson D, Lynch D . Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011; 21(12):2455-65. DOI: 10.1007/s00330-011-2223-2. View

18.

Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C . The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology (Oxford). 2021; 61(4):1600-1609. DOI: 10.1093/rheumatology/keab615. View

19.

Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View

20.

Solomon J, Olson A, Fischer A, Bull T, Brown K, Raghu G . Scleroderma lung disease. Eur Respir Rev. 2013; 22(127):6-19. PMC: 4103193. DOI: 10.1183/09059180.00005512. View